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Abstract 
 
The small antifungal protein secreted by Penicillium chrysogenum (PAF) inhibits the growth 
of important zoo pathogenic filamentous fungi, including members of the Aspergillus family. 
It was shown previously that PAF has no toxic effects on mammalian cells in vitro. We 
carried out safety experiments by investigating the in vivo effects of PAF by inoculating adult 
C57/B16 mice with PAF intranasally. Animals were randomly divided into six groups and 
subjected to different PAF concentrations, up to 54 µg, either once a week for up to 8 weeks 
or once every day for two weeks. Animals neither died due to the treatment nor were any side 
effects observed. Histological examinations did not find any pathological reaction in the liver, 
in the mucous membrane of the nose, and in the lungs, even in the highest concentration used. 
Mass spectrometry revealed that ZZZ. The effect of the drug on the skin was examined in an 
irritative dermatitis model by measuring the thickness of the ears. This proved to be the same 
following PAF application as in control (23.8±9.2 vs. 22.5±5.0 µm, respectively) and 
significantly less than when treated with phorbol-12-myristate-13-acetate (PMA; 
57.5±29.2 µm) used as positive control. Histological changes relative to control were present 
only in the case of PMA. Positron emission tomography was used to follow potential 
inflammation of the lungs. Neither the application of control saline nor that of PAF induced 
any inflammation while the positive control lipopolysaccharide did. Since no toxic effects of 
PAF were found either in intranasal application or in local external treatment, our result is the 
first step for introducing PAF as potential antifungal drug in human therapy. 
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Introduction 
 
Aspergillosis is one of the most severe human diseases caused by fungi threatening 
especially immunodeficient patients. The condition caused by various pathogenic Aspergillus 
species affects particularly the lungs. The most important species in this respect is Aspergillus 
fumigatus which preferentially colonizes caverns caused by previous diseases such as 
tuberculosis (21). It can cause allergic bronchopulmonary aspergillosis, pulmonary 
aspergilloma and invasive aspergillosis. In the latter the symptoms can be cough, fever, low-
grade chest pain, dyspnea and hemoptysis (2) while in allergic bronchopulmonary 
aspergillosis malaise, fever, presence of sputum plugs and purulent sputum, cough, chest pain, 
and hemoptysis can be observed beside the symptoms of asthma (23). The pulmonary 
aspergilloma can cause hemoptysis or it can be without symptoms. Other symptoms can be 
present due to the underlying pulmonary disease (ZZZ). Although a number of antifungal 
drugs are in use, there is a rising tendency of resistant strains leading to a high mortality rate 
(7), thus rendering the finding of new antifungal treatments of high interest. 
Filamentous fungi produce a wide spectrum of defensive proteins some of which, 
including the antifungal protein secreted by Penicillium chrysogenum (PAF; 13), are designed 
to hinder the growth of other fungi. PAF is a low molecular weight, basic, and cysteine-rich 
protein which has a homology with other antifungal proteins produced by other fungi. PAF 
inhibits the growth of various pathogen fungi including A. fumigatus, A. nidulans, A. niger, 
Botrytis cinerea (8). It causes an increased production of reactive oxygen radicals, reduces the 
metabolism of the fungal cells, and initiates an increased potassium efflux (8). PAF enters the 
cells via an active transport mechanism (16) and acts intracellularly, probably through hetero-
trimeric G-protein signaling (10, 14). It causes the hyperpolarisation of the membranes of the 
fungal cells, which leads to the disintegration of the membranes and, consequently, an 
apoptosis-like phenotype appears. Furthermore, reactive oxygen species oxidize intracellular 
proteins, lipids, and nucleic acids, causing not only the disintegration of the cellular 
membranes but also that of the mitochondria (20). These toxic effects, when they reach a 
critical limit, also contribute to the programmed cell death of the affected fungi (6). 
In fungal colonies treated by PAF the number of cells showing apoptotic signs 
including increased phosphatidylserine externalization and DNA fragmentation are increased 
compared to control colonies while the proportion of the necrotic cells remains the same (10). 
On the other hand, in a variety of mammalian cells PAF had no toxic effects. The ionic 
currents of neurons and astrocytes, the potassium and L-type calcium currents of skeletal 
muscle fibers were not altered. No toxic effects were found on endothelial cells with MTT 
assay ZZZ and only a minor pro-inflammatory effect was observed on human blood incubated 
with PAF when the level of cytokines was measured (22). 
The glucose analog 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) based positron emission 
tomography (PET) imaging is a very sensitive modality for the detection of metabolic activity 
of tissues. 18FDG uptake of infectious processes – mainly due to the presence of macrophages 
– has already been reported (Knight et al. 1996), suggesting that 18FDG based PET (FDG-
PET) can accurately be used for staging mediastinal diseases. The innate host defense system 
against Aspergillus includes phagocytic cells (peripheral blood monocytes, macrophages, 
neutrophils, etc.) (Walsh et al. 2005). Several mechanisms have been proposed as the basis for 
18FDG uptake into the inflammatory cells but they all conclude that cells accumulate 18FDG 
with high concentration, depending upon the degree of stimulation, which is a function of 
inflammatory activity (Basu et al. 2010). 
We developed an animal model for exploring the possible effects of PAF in living 
mice and we used a new non-invasive small animal PET imaging technique to prove that the 
drug is not toxic. Employing these techniques, this is the first study to indicate that the low 
molecular weight antifungal protein PAF has no toxic effects in vivo. Although further 
investigations should be carried out in vivo, including safety and efficacy studies, our results 
support the possible therapeutic application of PAF against aspergillosis in humans. 
Part of this work has been presented to the Hungarian Physiological Society (17). 
Materials and Methods 
 
Purification of PAF 
Purification of PAF was carried out as described previously (22). Briefly, P. 
chrysogenum NCAIM 00237 was grown in a sucrose (20 g/l)–NaNO3 (3 g/l) minimal medium 
for 72 h at 25°C with shaking (13). Mycelia were removed with centrifugation and the low 
molecular weight protein fraction of the supernatant was separated in Amicon Stirred Cells 
(Millipore, Billerica, MA, USA). PAF was purified with ion exchange chromatography on a 
CM Sephadex Fast Flow column (Amersham-Pharmacia, Uppsala, Sweden). The quality of 
the preparation was always checked with SDS-PAGE on pre-cast Novex 16% Tris/glycine 
gels (Invitrogen Life Technologies, Carlsbad, CA, USA), where protein bands were visualized 
with Coomassie Brilliant Blue R staining. PAF was dissolved in physiological saline (ZZZ) 
for the in vivo experiments. 
 
Model of PAF-induced lung effects 
12 weeks old C57/Bl6 mice of both sexes were used in all in vivo experiments. First the 
mice were randomized into five groups (a control group and mice treated with 0.1, 0.5, 2.5, 
and 5 µg PAF dissolved in physiological saline; 10 animals per group). The control group was 
treated with drug free physiological saline. Mice were slightly anesthetized with 
penthobarbital (50 mg/kg, 4 mg/ml concentration, 250 µl per mouse ZZZ) intraperitoneally 
then the above solutions were administrated by pipettes into the nose of the animals in a 50 µl 
final volume. Under these conditions the solution reaches the lungs through normal breathing. 
The efficiency of the procedure was tested by applying a dye solution (see Supplementary 
Figure). The animals were treated weakly for 8 weeks. An extra group (n=6) was treated with 
a very high dose of PAF (54.55 µg, 2727.5 µg/kg ZZZ) for 5 weeks. In this group blood 
samples were taken before and at the end of the application of the drug. To investigate the 
acute effect of PAF two groups of mice (10 animals per group) were treated daily for two 
weeks. The control group was treated with PAF free physiological saline while the protein 
was administrated in 5 µg dose in the other group of animals. 
ZZZ To explore the possible side effects of PAF, in both type of experiments the lungs, 
the kidneys, and the liver of the animals were examined histologically in each group. ZZZ kell 
ez itt? 
 
Model of LPS-induced acute lung inflammation 
For induction of acute lung inflammation, C57/Bl6 mice were divided into 3 groups, 
slightly anesthetized with pentobarbital and physiological saline (n=4), PAF (2188 µg/ml or 
5470 µg/kg; n=4), or lipopolysaccharide (LPS, Escherichia coli serotype 055:B5; Sigma-
Aldrich; 250 µg/kg; n=7 ZZZ) was instilled intratracheally in a total volume of 50 µl 
physiological saline. This dose was based on previous studies (19). Animals recovered 
quickly from the procedure with only mild discomfort. ZZZ 
 
Histological examination 
The weight of the removed lungs and livers were measured. Then tissue samples were 
fixed in 8% buffered formalin (24 h) and embedded in paraffin wax (Shandon Pathcenter, 
Thermo-Shandon, USA). 4 µm sections were cut and Haematoxylin-Eosin (H&E) staining 
was performed. The samples were investigated with a LEICA DM 2500 microscope equipped 
with a LEICA DFC 420 camera (Leica Microsystems, Germany) and the images were 
acquired using LEICA Application Suite (LAS) V3 software. 
 
Sample preparation for mass spectrometry 
PAF treated and control animals were sacrificed and the lungs were immediately 
frozen in liquid nitrogen and kept on -70ºC until analysis. The frozen lung tissue was 
homogenized with homogenizer chilled in liquid nitrogen and the homogenate was dissolved 
in ice-cold lysis buffer (50 mM Tris, 1 mM EDTA, 17 mM beta-mercaptoethanol, 0.5% 
Triton-X100), centrifuged at maximum speed (ZZZ) at 4ºC and the supernatant was collected. 
The proteins from the homogenate were precipitated with 6 volume (ZZZ) of cold acetone 
overnight at -20ºC then centrifuged (ZZZ) and the supernatant was discarded. The pellet 
containing the proteins was dried and re-dissolved in 25 mM ammonium bicarbonate. For 
protein concentration measurement the Bradford method was utilized (ZZZ). For trypsin 
digestion 100 µl sample and 0.25 ng trypsin was used. The digestion was carried out at 37ºC 
overnight than the reaction was stopped by the addition of 1 µl formic acid and lyophilized. 
For mass spectrometry measurements the proteins were re-dissolved in 0.1% formic acid and 
10 µg protein was used for each analysis. 
 
Determination of relative PAF amounts in lung samples by mass spectrometry 
MRM/SRM method (ZZZ) was developed for PAF measurement. After several rounds 
of experimental design and optimization the following MRM transitions were found to be 
specific for PAF: 1041.4/1038.6, 1041.4/649.5, 1249.1/1222.7 and 1249.1/1245.9. Applying 
these MRM transitions, PAF concentration was measured using positive mode MRM scans 
performed on a 4000 QTRAP (ABSciex, ZZZ) mass spectrometer using NanoSpray II 
MicroIon Source and controlled by the Analyst 1.4.2 software (ABSciex). The spray voltage 
was 2800 V, the nebulizig gas was 50, the curtain gas was 10, the source temperature was 
70ºC and the de-clustering potential was 130 V. The liquid chromatography was done on an 
EasynLC II nano HPLC (Bruker, ZZZ) and the peptide mixture was separated on Zorbax 
300SB-C18 (5x0.3 mm, 5 µm pores size) column. 30 min acetonitrile/water gradient was used 
for separation including the following steps: 0% to 100% acetonitrile during 10 minutes, 
100% acetonitrile for 5 minutes and 100% to 0% acetonitrile during 5 minutes. The flow rate 
was 300 nl/min during the analyses. For the determination of PAF concentration the area 
under the curve of the acquired spectra was calculated. 
 
Irritant dermatitis 
The irritant dermatitis was evoked as described previously (1) with minor modifications. 
Namely, stock solutions of PAF and phorbol-12-myristate-13-acetate (PMA) were prepared in 
saline and DMSO, respectively and then both compounds were further diluted in hydrophilic 
cream (Unguentum hydrophylicum non-ionicum, Pharmacopoeia Hungarica VIII). Animals, 12 
female C57/BL6 mice, were randomized into three groups (control, PMA, and PAF) and the 
thickness of their ears was measured. Mice were treated by smearing 4x10 µL of vehicle (saline, 
0.9% NaCl ZZZ), PMA (500 µg/ml), or PAF (100 µg/ml) onto the inner and outer surface of both 
ears. After 24 hours, thickness of the ears was measured again and tissue samples were taken for 
histology. 
 
Positron emission tomography (PET) 
The glucose analog 18FDG (2-[18F]fluoro-2-deoxy-D-glucose) was synthesized and 
labeled with the positron-decaying isotope 
18
F according to a previously described method 
(5). Images were collected using the MiniPET-II system (http://www.minipetct.hu), a 
dedicated small animal PET scanner (9). The normalized and random corrected list mode data 
was to 0.27 x 0.27 x 1.37 mm pixel sized images. 
FDG-PET experiments were carried out on mice randomized into three groups (control, 
n=4; PAF, n=4; LPS, n=6). The animals were fasted for a minimum of 6 hours before 
undergoing PET. After an injection of 4-6 MBq of 18FDG in 150 µl of phosphate buffered 
saline (PBS) via the tail vein, a dynamic PET scan was acquired using the small animal PET 
camera. Mice were maintained under isoflurane anesthesia during the injection and scanning 
periods. They were kept warm while under anesthesia to maintain a body temperature at 35ºC. 
Three-dimensional regions of interest (ROI) were manually drawn around the edge of 
the lung activity by visual inspection using BrainCad software (http://www.minipetct.hu). The 
standardized uptake value (SUV) was calculated by multiplying the mean concentration 
activity in the ROI with mouse weight and dividing by injected dose. 
 
Blood collection and cell counting 
Mice were slightly anesthetized with pentobarbital and 200 µl blood was collected into 
a cup containing 40 µL acid citrate dextrose (ACD, Vacutainer tube Becton Dickinson 
Diagnostics-Preanalytical Systems Plymouth, UK) by puncture of the retrobulbar venous 
plexus with a 1.5 mm diameter glass capillary. ACD anticoagulated whole blood was 
analyzed by Siemens Advia-120 hematology analyzer with Multi Species software (Deerfield, 
IL, USA), counting the number of the white blood cells and the neutrophil granulocytes (15). 
In addition, the level of liver enzymes and the ions in the plasma were measured to further 
explore the possible toxic effects of PAF. 
 
Animal care 
Animal experiments conformed to the guidelines of the European Community 
(86/609/EEC). The experimental protocol was approved by the institutional Animal Care 
Committee of University of Debrecen. 
 
Chemicals and statistical analysis 
Chemicals, unless otherwise stated, were purchased from Sigma (St. Louis, USA) and 
were of analytical grade. Averages were expressed as means±standard error (SE) of the mean. 
Significance of the differences between control and treated animals was assessed using one 
way analysis of variance (ANOVA) and all pair wise multiple comparison procedures 
(Student-Newman-Keuls Method). 
Results 
PAF was tested in vivo in several doses (0.1-54.55 µg) either for a short (2 weeks) or for a 
prolonged period (5-8 weeks) on mice. In case of the former PAF was applied daily while in 
case of the latter it was administered once a week. Since the most probable application of PAF 
in human therapy would be to treat aspergillosis which would require the drug to be 
introduced via the airways, presumably using inhalators, we attempted to simulate this 
condition by introducing PAF to mice via the airways. The drug was thus introduced after 
anesthesia through the nose while the applicability of the method, that is whether the liquid 
thus applied actually reached the alveoli, was tested in independent experiments (see 
Supplementary Figure). During the course of the experiments we did not observe the death of 
an animal due to the drug application even in the highest concentration applied. Furthermore, 
the weight and physical activity of the animals remained unchanged during the study period. 
To test for possible morphological alterations due to the application of PAF, 
histological examination of the lungs, nose, and liver of the animals were carried out. As 
shown in Figure 1 we did not observe any signs of pathological alterations in the lungs 
(Figure 1A), in the nose (Figure 1B), and in the liver (Figure 1C) tissue neither following the 
short, nor following the prolonged application of the protein. In the highest dose (54.55 µg) of 
PAF both the white blood cell count (1.94±0.15 and 1.83±0.18 1010/l; control vs. treated, 
respectively; p>ZZZ) and the percentage of neutrophils remained unchanged (2.08±0.57 and 
2.10±0.29 %; control vs. treated, respectively; p>ZZZ). Furthermore, the concentration of 
liver enzymes and ions in the blood did not show a significant elevation after PAF treatment 
(Table 1). These results clearly established that the application of PAF neither induced any 
gross changes in organ morphology nor did it initiate an overall immune response in the 
animals. 
To prove the efficiency of the PAF application – that is to clearly establish that PAF 
was indeed present in the lungs – mass spectrometry was used to determine the relative PAF 
amounts in the lungs of PAF treated mice. The relative amount of PAF was measured in 
control (K1-4) and PAF treated lung samples. The results demonstrate the presence of PAF in 
the lungs of the PAF treated animals (Figure X). – ezt még átírom a tényleges eredmények 
függvényében Csosz Eva. 
Although, as mentioned above, the human application of PAF would most likely be 
through inhalation, it cannot be excluded that the drug comes in contact with the skin, or 
surface application will be need as well. To test for the possibility that PAF could induce 
local, contact inflammation, a contact dermatitis model was used where the swelling of the 
ears was measured. PAF treatment did not cause the swelling of the ears in the dose used. On 
the other hand, PMA, used as a positive control, induced a clear edema (Figure 2A), 
indicating inflammation. This latter observation underlined that the model was sensitive 
enough to detect any inflammation. In particular, ears of mice in the PMA group (n=4) were 
markedly thicker due to edema formation (57.5±29.2 µm) than their control counterparts. In 
contrast, PAF did not induce any inflammation, the thickness of the ears was almost identical 
to the control (22.5±5.0 and 23.8±9.2 µm; in the control and in the PAF treated group, 
respectively, n=4 for both groups; Figure 2B). 
To test the transient effects of PAF application on the lungs we developed a new non-
invasive method. FDG-PET experiments were carried out on 14 mice, randomized into 3 
groups. The 3D image of the body was reconstructed from the acquired images and the lungs 
were identified as Regions of Interest (ROI; see Figure 3 left panel). The intensity of 18FDG 
accumulation within the ROI was assessed as a measure of inflammation. This method 
enabled us to give an estimate of and to follow any occurring inflammatory reactions in 
individual mice. 
Figure 3 presents reconstructed images from mice that were treated with physiological 
saline (Figure 3A), saline containing PAF (2188 µg/ml; Figure 3B) or saline containing LPS 
(100 µg/ml, Figure 3C) as positive control. It is clearly visible from the images that while 
PAF itself did not alter the emission intensity in the lungs as compared to control, LPS caused 
a marked increase in emission, indicating the presence of inflammation. These observations 
were quantified by calculating the emissions in the ROI. Pooled data showed a significant 
decrease in PAF treated group (0.50±0.01 SUV, n=4) compared to the control (0.72±0.04 
SUV, n=4) and a significant elevation in the LPS treated animals (0.99±0.09 SUV, n=6). To 
validate the PET results, we sacrificed some animals from each group and conducted 
histological examination. H&E staining of the sections confirmed the absence of any 
inflammation in the control and the PAF-treated, while the presence of extensive 
inflammation in the LPS-treated animals (Figure 3A-C right panel). 
Taken together our results presented here confirmed that PAF, in the intended 
therapeutic concentration, has no harmful effects in vivo. Furthermore, the methods 
introduced here enable the non-invasive characterization and follow-up of occurring 
inflammation of the lungs and the efficacy of the treatment. 
Discussion 
 
Aspergillus species have emerged as important causes of morbidity and mortality in 
immunocompromised patients (18, 2, 12) The treatment of aspergillosis might include 
chemotherapy and surgical treatment. The primary antimycotic agents against invasive 
pulmonary aspergillosis are voriconazole and amphotericin-B (D-AMB) ZZZ. The lipid 
formulations of amphotericin-B (LFABs), itraconazole, and caspofungin are used for salvage 
therapy while posaconazole is commonly used for prophylaxis of invasive aspergillosis in 
immunosuppressed patients. In allergic bronchopulmonary aspergillosis, itraconazole and 
corticosteroids are recommended. Patients with aspergillomas usually need surgical resection 
or intracavitary antifungal therapy. Chronic cavitary pulmonary aspergillosis and chronic 
necrotizing pulmonary aspergillosis require long-term antifungal therapy (24). Despite the 
best treatment available, survival rate at 12 weeks is around 70% among voriconazole-treated 
and around 60% among D-AMB–treated patients with invasive pulmonary aspergillosis (3). 
Since the efficacy of the antifungal therapy is not complete in any other type of aspergillosis 
either, the development and introduction of new antimycotic agents into human therapy would 
be beneficial beyond doubt. 
ZZZ ide PAF hatása a gombákra. Koncentráció és a koncentráció amit mi használtunk 
a mostani mérésekben. The Penicillium-derived anifungal protein has been shown to be very 
effective to inhibit the growth of most zoo-pathogen fungi in vitro (ZZZ). The effects of PAF 
include ZZZ (ZZZ). These effects were achieved at a concentration of ZZZ. The 
concentrations used in these experiments were thus determined on the basis of our earlier 
experiments (10), where membrane hyperpolarization and obvious signs of apoptosis in 
Aspergillus hyphae or protoplasts were observed after treatment with PAF. In our study we, 
therefore, used PAF concentrations ZZZ 10-50 µg/ml. 
ZZZ Ide a mass spectr data hogy PAF tenylegesen jelen volt a tudoben. 
It is important to stress that mice treated with PAF showed no sign of any change in 
their behavior. They maintained regular activity as assessed by their normal water and food 
intake as well as the amount of spontaneous exercise they did (distance and speed of running 
in an activity wheel; data not shown ZZZ). These are clearly in line with our earlier in vitro 
studies where we found no toxic effects of PAF on mammalian cells, on neurons and on 
skeletal muscle fibers in particular (22). In those studies a wide variety of cells – including 
neurons, astrocytes, and skeletal muscle fibers – were examined to explore whether PAF has 
any acute effect on these cells similar to those described on fungal cells. The 
hyperpolarization-activated nonspecific cationic current and the depolarization-activated 
current of bushy cells from the ventral cochlear nucleus were not altered significantly. The 
activation thresholds and the amplitudes of depolarization activated K+ currents of 
hippocampal neurons were not affected by PAF. No effects were observed on astrocytes 
either. PAF also failed to alter significantly the current of the delayed rectifier potassium 
channel and L-type Ca2+ currents of the skeletal muscle fibers. Taken together, our present 
observation with in vivo application of PAF clearly suggests that this antifungal drug – in the 
concentration range used – has no effect on the spontaneous activity of the treated animals. 
Several organs, including the lungs, the liver, and the kidneys, taken from the group 
treated for 2 weeks once a day or for 8 weeks treated once a week underwent histological 
examination. The organs were always taken from the animals that received the highest ZZZ 
concentration of PAF. The fact that no morphological change was observed in these 
experiments strongly argues that PAF has no ZZZ. This observation, in case of the liver, the 
kidneys, and the skeletal muscles, is substantiated by the finding that liver enzymes, the 
concentration of the important ions, and creatine kinase levels, respectively, in blood of PAF 
treated animals were essentially identical to those of control animals (Table 1). 
In earlier experiments the possible in vitro pro-inflammatory action of PAF was 
examined on human blood (ZZZ). In those studies blood samples were incubated with 
different concentrations of PAF and the levels of IL-6, IL-8 and TNF-α were measured. The 
rise in the production of cytokines was minimal compared to the effect of LPS. Here we 
examined ZZZ ide blood data on WBC and neutrophil and … 
These observations are in line with the data presented here using the FDG-PET 
technique. ZZZ Ide, hogy a PET alkalmas erre ref ZZZ. The PAF-induced decrease in the 
SUV values during the PET experiments shows also positive or at least no toxic effects of the 
drug. Similar data were found on some antineoplastic drugs in cell cultures (11). 
Earlier studies have demonstrated that PAF has inhibiting effects on several 
dermatophytes, which are a group of morphologically and physiologically related molds 
affecting the keratinous tissue of vertebrates (4). This raises the possibility that PAF could 
have a potential therapeutic use in dermatophytosis. Such application would inevitably require 
that local application of PAF on the skin should not evoke any local inflammatory response. 
ZZZ model ref ZZZ Our results from the irritative dermatitis experiments prove that PAF is a 
potential candidate for the treatment of topical and systemic dermatophytosis. 
These results proved the safety of PAF, so we can soon move to experiments 
evaluating the efficacy of PAF as a promising antifungal therapy. 
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Figure legends 
Figure 1. Histological investigation of various mouse tissues after PAF treatment 
A. Haematoxylin-Eosin stained sections of lungs from control (left) and PAF treated (5 µg; 
right) mice at two magnifications. Section of nose (B) and liver (C). There is no pathological 
sign of PAF treatment on these tissues. 
Figure 2. Lack of inflammatory effects of PAF in an irritant dermatitis model on mouse ears 
Irritant dermatitis reaction was induced in mice by smearing PMA on both sides of the ears. 
A. Sections of ears were stained with haematoxylin and eosin. PMA-induced irritative 
dermatitis resulted in edema formation in the dermis. PAF-treated mice showed no signs of 
inflammation. (Scale bar corresponds to 50 µm for the images). B. Average increase of ears’ 
thickness. * corresponds to significant (p<0.05) difference from control. 
Figure 3. Detection of inflammatory effects of PAF in mouse lungs by Mini PET examination 
FDG-PET images (left column) and H&E stained lung sections from control (A), PAF (B) 
and LPS (C) treated mouse. ROIs marked by red lines on the tranzaxial PET pictures 
represent the place of lung where the SUV calculations have done. Note the higher intensity 
areas on the tranzaxial and coronal PET image (marked with arrow) and the extensive acute 
inflammation in the lung in the presence of LPS. 
Figure X. Relative PAF amount determined by mass spectrometry. 
The figure shows the PAF amounts in different lung samples. K1, K2, K3 and K4 represent 
the lung from control, untreated mice, P0, P1, P2, P3 and P4 represent the lung from PAF 
treated mice and PAF represents the positive control containing lung from untreated mice plus 
500 fmol PAF. The bars represent the results for duplicate analyses. 
 
